It is known that low-level CXCR4-using variants may be selected upon CCR5 antagonist treatment [42]–[45], but it remains to be determined whether their presence predicts the outgrowth of a major CXCR4-using variant during natural infection or is of pathological relevance in untreated individuals. The gene discussed is CCR5; the disease is infection.